关于「 biology」的内容列表
Hong Kong stocks of biomedical plate low, WuXi PharmaTech (02359.HK) opened down 2.78%, WuXi Bio (02269.HK) opened down 2.77%, Tiger medicine (03347.HK), BeiGene (06160.HK) and so fell.
On December 6, according to the official announcement of the decentralized biotechnology protocol Molules, Moldule will cooperate with the Pump.science and the DeSci project BIO Protocol to establish the DeSci Ecosystem Fund, with a funding scale of 166 million BIOs (half of the allocation of Molecules), in order to accelerate the scientific intellectual property chain. Molecular said it has repurchased $100,000 worth of RIFs and $100,000 worth of UROs to reaffirm its commitment to support RIFs,...
Humanode, a biometric blockchain project, is launching an ecosystem fundraising initiative worth $10 million to "support and nurture its on-chain projects". It is not clear who is involved in the fundraising, but the team noted that it was backed by "funds and angel investors". The project will be on Humanode EVM, using cryptographic biometrics to defend against Sybil ". Humanode plans to partner with projects selected for the program to provide not only funding, but also technology...
Hong Kong biotechnology stocks strengthened, Fudan Zhangjiang (01349.HK) rose 28%, Junshi Biosciences (01877.HK), Tiger Pharmaceutical (03347.HK), WuXi AppTec (02359.HK), WuXi AppTec (02269.HK), Kang Xinuo Biological (06185.HK) and other stocks rose more than 10%.
On September 25th, according to the official website of the US Congress, on September 23rd local time, there was another progress in the legislation of the US Biosafety Act. In the latest amendment, WuXi Biologics has been removed, but WuXi AppTec, BGI, BGI and its subsidiary Complete Genomics are still listed. At the same time, the plan is to be renamed the "Prohibition of Foreign Access to US Genetic Information Act", and will further focus on human data-related business. For the aforementione...
Hong Kong biomedical stocks rose straight in the afternoon, WuXi Bio (02269.HK), WuXi PharmaTech (02359.HK) rose more than 6%, Tiger Pharmaceutical (03347.HK) rose nearly 4%, BeiGene (06160.HK), Kingsree Biotechnology (01548.HK) rose more than 2%.
Class A shared biological products continued to decline, Kangle Guard fell nearly 7%, Zhixiang Jintai, Bepsy, Baike Bio, Wantai Bio, Zhifei Bio and so on fell.
Hang Seng Index continued to strengthen up more than 1%, WuXi Bio (02269.HK), WuXi AppTec (02359.HK) led the component stocks. Hang Seng Technology Index rose to 1.5%.
